Global Blood Therapeutics has enrolled its first patient in the ZEPHYR Phase 2a clinical study assessing the safety and effectiveness of GBT440 in treating hypoxemia (low levels of oxygen in the blood) in patients with idiopathic pulmonary fibrosis (IPF) who are on supplemental oxygen at rest. GBT440 is an…
Blocking a particular pathway — called c-Jun N-terminal Kinase (JNK) — may reduce lung remodeling and fibrosis, researchers said in a multi-part study reporting the effects of a JNK inhibitor in a mouse model and, subsequently, in a clinical trial involving patients with idiopathic pulmonary fibrosis (IPF). The study, “JNK inhibition reduces lung…
A higher fat-free mass index — a measure that takes a person’s muscle mass into account — predicts better survival in patients with pulmonary fibrosis, while body mass index (BMI) does not, according to a new study. Although researchers could not explain how body composition impacts disease progression, the findings may provide another…
Hello Pulmonary Fibrosis Community! Technology is amazing! For a little over a year Facebook has been allowing its members to do live videos from their pages. I tried this out on my own Facebook page about three months ago, and am really enjoying being able to reach out and…
Researchers may have discovered a key mechanism underlying pulmonary fibrosis (PF) — the failure of a particular group of lung stem cells to regenerate, hindering the repair of lung tissue in PF. The study, “Hyaluronan and TLR4 promote surfactant-protein-C-positive alveolar progenitor cell renewal and prevent severe pulmonary fibrosis in mice,” was…
Treatment with PBI-4050 may be a safe and effective therapy for patients with idiopathic pulmonary fibrosis (IPF), according to preliminary results from a Phase 2 clinical trial developed by ProMetic Life Sciences. The study (NCT02538536) has enrolled 40 IPF patients at six different sites in Canada to…
Family members of idiopathic pulmonary fibrosis (IPF) patients across generations — their children and grandchildren — recently came together in London recently to sing an emotional rendition of Rachel Platten’s hit “Fight Song,” part of a global campaign (#fightsongchallenge) to promote disease awareness. The campaign encourages IPF patients and their…
iBio, a developer of plant-based biotechnology, has announced the completion of expanded product development capacity at its subsidiary, iBio CMO, jointly owned with affiliates of Eastern Capital, for the production of pharmaceutical proteins in hydroponically-grown green plants and the large-scale manufacture of biological pharmaceutical products. iBio is…
Bristol-Myers Squibb has acquired exclusive worldwide rights to Nitto Denko’s antifibrotic drug development efforts with siRNA molecules. In addition to the Japanese company’s lead compound ND-L02-s0201, currently in a Phase 1b clinical trial (NCT02227459) for advanced liver fibrosis, the agreement gives Bristol-Myers the right to obtain licenses for other…
Australian and German companies, AdAlta and XL-protein, have entered into a collaboration to create a long-acting form of AdAlta’s AD-114, an antibody-based treatment for idiopathic pulmonary fibrosis (IPF) and other fibrotic conditions. According to the agreement, XL-protein will contribute with their PASylation technology, attaching a string of amino acids that…
Get regular updates to your inbox.
